| name | endo-avoid-gh-igf1-monitoring-pregnancy |
| description | This skill advises against measuring GH or IGF-1 in pregnant patients with acromegaly because placental GH variant interferes with assay interpretation. Use when evaluating hormone testing in a pregnant acromegaly patient. |
Avoid monitoring GH and/or IGF-1 levels during pregnancy
STEP 1 — Gather Information
Confirm pregnancy status and existing acromegaly diagnosis; document current symptoms (headache, visual changes) and prior visual field testing if macroadenoma present.
STEP 2 — Rule In / Rule Out
If the patient is pregnant and has acromegaly → proceed to avoid GH/IGF-1 monitoring; otherwise, follow standard IGF-1/GH monitoring for acromegaly.
STEP 3 — Classify or Stratify
Classify as pregnant acromegaly patient where GH and IGF-1 assays are unreliable due to placental GH variant secretion.
STEP 4 — Decide
Refrain from ordering GH or IGF-1 levels; manage based on clinical assessment, symptom review, and serial visual field testing if macroadenoma is present.
Clinical Guardrails / Mimics / Pitfalls
Do not interpret elevated IGF-1 as disease progression; do not adjust medical therapy based on these levels; placental GH variant causes false elevations and cannot be distinguished by conventional assays. Rely on clinical symptoms and visual fields instead.
Concrete Clinical Example
A 32‑year‑old woman with previously treated acromegaly presents at 16 weeks gestation with mild headaches; the clinician resists ordering IGF-1, documents stable symptoms, and schedules visual field testing due to known macroadenoma.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI: 10.1210/jc.2014-2700
